Q-omics provides the consensus-scored CCDC54 profile across patient tissues and cancer cell-line models. CCDC54 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CCDC54 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, CCDC54 RNA expression shows 12,100 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, THCA, and THYM as cancer lineages where CCDC54 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC54 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC54 survival associations across molecular data types. CCDC54 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC54 RNA expression–survival associations across cancer types. High CCDC54 expression shows unfavorable associations in UCEC, STAD, KIRC and THCA, but favorable associations in UCS and OV. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for CCDC54 RNA expression.
This table summarizes CCDC54 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC54. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC54 shows lower tumor expression in THCA, LUAD, KIRC, BRCA and LUSC and higher tumor expression in LIHC. The THCA box plot shows higher CCDC54 RNA expression in normal versus tumor tissue (log2 FC = −0.265, t-test p < 0.001).
This table shows molecular features associated with CCDC54 in patient tissues and cancer cell lines. In patient samples, CCDC54 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC54 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
